Literature DB >> 24115584

Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model.

Qing-Shuo Zhang1, Laura Marquez-Loza, Andrea M Sheehan, Kevin Watanabe-Smith, Laura Eaton, Eric Benedetti, Angela Major, Kathryn Schubert, Matthew Deater, Eric Joseph, Markus Grompe.   

Abstract

Fanconi anemia (FA) patients suffer from progressive bone marrow failure and often develop cancers. Previous studies showed that antioxidants tempol and resveratrol (RV) delayed tumor onset and reduced hematologic defects in FA murine models, respectively. Here we tested whether antioxidants N-acetylcysteine (NAC) or RV could delay cancer in tumor prone Fancd2(-/-) /Trp53(+/-) mice. Unlike tempol, neither compound had any significant chemopreventive effect in this model. We conclude that not all anti-oxidants are chemopreventive in FA. In addition, when given to Fancd2(-/-) mice, NAC helped maintain Fancd2(-/-) KSL cells in quiescence while tempol did not. The mechanisms behind the different actions of these antioxidants await further investigation.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Fanconi anemia; N-acetylcysteine; antioxidants; chemoprevention; resveratrol

Mesh:

Substances:

Year:  2013        PMID: 24115584      PMCID: PMC3946268          DOI: 10.1002/pbc.24780

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Cancer in Fanconi anemia.

Authors:  Blanche P Alter; Mark H Greene; Isela Velazquez; Philip S Rosenberg
Journal:  Blood       Date:  2003-03-01       Impact factor: 22.113

Review 2.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

Authors:  Hyungjin Kim; Alan D D'Andrea
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

3.  Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Authors:  Sung-Jun Park; Faiyaz Ahmad; Andrew Philp; Keith Baar; Tishan Williams; Haibin Luo; Hengming Ke; Holger Rehmann; Ronald Taussig; Alexandra L Brown; Myung K Kim; Michael A Beaven; Alex B Burgin; Vincent Manganiello; Jay H Chung
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

4.  Clinical development plan: N-Acetyl-l-cysteine.

Authors:  G J Kelloff; J A Crowell; C W Boone; V E Steele; R A Lubet; P Greenwald; D S Alberts; J M Covey; L A Doody; G G Knapp
Journal:  J Cell Biochem Suppl       Date:  1994

5.  Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice.

Authors:  Ramune Reliene; Robert H Schiestl
Journal:  DNA Repair (Amst)       Date:  2006-06-15

6.  Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice.

Authors:  Scott Houghtaling; Laura Granville; Yassmine Akkari; Yumi Torimaru; Susan Olson; Milton Finegold; Markus Grompe
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

7.  Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence.

Authors:  Xiaoling Zhang; Daniel P Sejas; Yuhui Qiu; David A Williams; Qishen Pang
Journal:  J Cell Sci       Date:  2007-04-03       Impact factor: 5.285

8.  Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.

Authors:  M Jang; L Cai; G O Udeani; K V Slowing; C F Thomas; C W Beecher; H H Fong; N R Farnsworth; A D Kinghorn; R G Mehta; R C Moon; J M Pezzuto
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

9.  Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells.

Authors:  S Suy; J B Mitchell; D Ehleiter; A Haimovitz-Friedman; U Kasid
Journal:  J Biol Chem       Date:  1998-07-10       Impact factor: 5.157

10.  Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice.

Authors:  Qing-Shuo Zhang; Laura Eaton; Eric R Snyder; Scott Houghtaling; James B Mitchell; Milton Finegold; Carter Van Waes; Markus Grompe
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

View more
  6 in total

1.  The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice.

Authors:  Qing-Shuo Zhang; Matthew Deater; Kathryn Schubert; Laura Marquez-Loza; Carl Pelz; David A Sinclair; Markus Grompe
Journal:  Stem Cell Res       Date:  2015-05-22       Impact factor: 2.020

2.  Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice.

Authors:  Qing-Shuo Zhang; Weiliang Tang; Matthew Deater; Ngoc Phan; Andrea N Marcogliese; Hui Li; Muhsen Al-Dhalimy; Angela Major; Susan Olson; Raymond J Monnat; Markus Grompe
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

Review 3.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

4.  Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model.

Authors:  Qing-Shuo Zhang; Matthew Deater; Ngoc Phan; Andrea Marcogliese; Angela Major; Eva C Guinan; Markus Grompe
Journal:  Pediatr Blood Cancer       Date:  2018-09-25       Impact factor: 3.167

Review 5.  Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia.

Authors:  Tafadzwa Chihanga; Sara Vicente-Muñoz; Sonya Ruiz-Torres; Bidisha Pal; Mathieu Sertorio; Paul R Andreassen; Ruby Khoury; Parinda Mehta; Stella M Davies; Andrew N Lane; Lindsey E Romick-Rosendale; Susanne I Wells
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

6.  Treatment of FANCA cells with resveratrol and N-acetylcysteine: a comparative study.

Authors:  Marta Columbaro; Silvia Ravera; Cristina Capanni; Isabella Panfoli; Paola Cuccarolo; Giorgia Stroppiana; Paolo Degan; Enrico Cappelli
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.